疗效增强的基因修饰 CD7 靶向异体 CAR-T 细胞疗法治疗复发/难治性 CD7 阳性血液系统恶性肿瘤：一项 I 期临床研究

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancie

放疗预处理增强 B7-H3-CAR-T 治疗实体瘤模型的疗效

Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.

我们的结果提示，B7-H3-CAR-T 疗法联合放疗可能是治疗实体瘤的一种有前景的方式。

CLL1 CAR-T 细胞疗法治疗复发/难治性急性髓系白血病成年患者的最新数据

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia.

靶向血液系统恶性肿瘤耐药机制的新型治疗策略：从 BCL2 抑制到免疫调节策略

Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches.

这些策略代表着向精准医学的范式转变，但毒性以及生物标志物驱动的耐药等挑战依然存在。

CD7 CAR-T 细胞用于复发/难治性 CD7 阳性急性髓系白血病患者

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

MICA/MICB 下调提升复发/难治性急性髓系白血病或骨髓增生异常肿瘤患者中 NKG2DL CAR-T 细胞的细胞持久性与临床活性

Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloi

急性髓系白血病中的检查点抑制剂及其他免疫疗法

Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia.

靶向 CD155 的 CAR-T 细胞降低白血病和实体瘤临床前模型中的肿瘤负荷

CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors.